Ear, nose and throat (ENT) surgery may be the oldest surgical specialty, but it certainly has not lost its lustre with age. It encompasses a wide variety of pathology, spanning all age groups regardless of gender, ethnicity or socio-economic status. The field of ENT (otorhinolaryngology) includes a broad range of procedures, often using advanced technology both at the bedside and in theatre. Recent decades have seen the discipline expand to include subspecialties like head and neck surgery, neuro-otology, anterior and lateral skull base surgery, allergology and paediatrics.
In South Africa (SA), where it is very apparent that there are economic barriers to diagnosis and treatment, we are faced with the co-existence of the developing and developed world. Health budgets, poor infrastructure and shortage of medical staff are some of the challenges regularly encountered. [1] Furthermore, there are individual clinicians and dedicated units who strive for the best outcomes by pioneering ground-breaking surgeries, regardless of limitations in resources -including head and neck cancer units using free flaps, endoscopic skull-base surgery using neuro-navigation and cochlear implant programmes, to name a few.
Almost 20% of general practitioner (GP) visits involve complaints arising from the ears, nose or throat. In the paediatric population, this figure rises to around 50%. [2] As of 31 March 2012, 38 236 medical practitioners are registered with the Health Professions Council of South Africa (HPCSA), of whom only 0.9% are ENT specialists (344 practitioners). [3, 4] In addition, almost 70% of the SA has the highest number of HIV-infected individuals in any country, with the highest prevalence among people between the ages of 15 and 49 years. [5] Up to 100% of HIV-positive patients will present with head and neck manifestations. [6] Oral candidiasis and rhinosinusitis were traditionally documented as the most common ENT manifestations of HIV. [7] However, with the institution of antiretroviral (ARV) rollout programmes, patients may present differently. This has been suggested by Tshifularo et al., [8] who found adenoid pathology, cervical lymphadenopathy and chronic suppurative otitis media to be the top three manifestations at Steve Biko Academic Hospital. While this may imply a change, it could be multi-factorial, rather than solely drug-related effects. More research is therefore needed from patients on long-term ARV therapy.
According to the World Health Organization (WHO), hearing impairment is the greatest sensory deficit globally. There are 360 million people worldwide suffering from disabling hearing loss (>40 db), more than half of whom live in low-and middleincome countries. [9] Of greater concern is that these people may not be identified as having hearing loss, because there are not enough screening programmes in place. [9] Perhaps most tragic, 50% of all causes of hearing loss are preventablecauses that can be alleviated by early prevention techniques, including screening programmes and early definitive management strategies. [9] HIV-positive people have an increased risk of developing hearing loss -primarily from the disease (non-iatrogenic), from opportunistic infections, or from the effects of drugs related to treatment. [10] Anti retroviral therapy (ART), alone or in combination with other treatments, could add to the overall toxic effect on hearing. [10] In SA, where the increase in MDR-TB has been linked to the HIV epidemic, patients on WHO-recommended MDR-TB second-line drug therapy are more likely to have nephrotoxicity and ototoxicity, the latter being permanent. [11] Some individuals may develop sudden profound sensorineural hearing loss following a single dose of aminoglycoside, highlighting the need to use it with caution even in routine medical practice. Harris et al. [11] found that 57% of MDR-TB patients developed high frequency hearing loss, and that 70% of HIV-positive patients were more likely to develop hearing loss than HIV-negative patients on MDR-TB therapy. As a consequence, HIV and TB co-infected individuals are a high-risk population for hearing loss, and without awareness and intervention, may constitute a new deaf community in sub-Saharan Africa (SSA) -a population that will require audiological and ENT services. [1] Despite SA being the most advantaged in Africa regarding access to audiology services, hearing aids and ENT interventions, Fagan and Jacobs [12] found that our country still only fulfilled less than half of the required service ratios compared with the UK. SA does not have adequate screening programmes for children, the elderly or high-risk populations.
The global burden of illness from chronic suppurative otitis media (chronic active otitis media) involves 65 -330 million individuals with otorrhoea, 60% of whom suffer from significant hearing impairment. [13] Prevalence varies in different population groups, with local prevalence rates in SSA ranging between 0.4 and 4.2% -50% of these cases presenting in children under 10 years. [14] Otorrhoea is treated at a primary care level in SA, and patients are generally referred to specialists only after treatment failure. Tiedt et al. [14] and Meyer et al., [15] undertaking local studies at different centres, highlight the delay in patients being referred to ENT services. In children who suffer associated hearing loss this delay has a negative impact on school performance. [14] In addition, Loock [16] and the aforementioned two local ENT departments investigated the microbial spectrum of otorrhoea in their respective communities. [14] [15] [16] [17] All of the local studies have identified Proteus mirabilis and Pseudomonas aeruginosa as the most prevalent pathogens. This differs from findings elsewhere in the world. Guidelines for the management of otitis media, aimed at a primary healthcare level, were released by the the National Department of Health in 2012. [18] Although very comprehensive, the recommended antimicrobials (topical or systemic), including oral amoxicillin, for chronic otorrhoea (non-responders) do not cover the majority of organisms encountered. However, topical fluoroquinolone eardrops with ear mopping covers 95% of organisms cultured and is not ototoxic. Should the first-line treatment fail then an antibiotic group with Gram-negative cover should be considered. [15] Patient profiles, disease projection and response to treatment all vary according to the location and population. In many spheres of medicine, we rely heavily on international sources, often adapting protocols and guidelines for local use. The above findings emphasise the need to promote local research.
Ideally, smaller surgical disciplines like ENT should capture data at local institutions and keep national registries for specific diseases. In doing so, the burdens of disease can be better managed, and local databases can also be used for auditing local services. Research should be integrated -across institutions, between disciplines, across departments and beyond economic barriers into the private sector -where pioneering work often goes unpublished. Comparative assessments of local versus international findings are also necessary, thereby facilitating a global perspective for SA ENT centres that will enable them to improve and compete with world leaders in the field.
Head and neck squamous cell cancer (HNSCC) is the sixth most common malignancy and the eighth leading cause of cancer death worldwide. [19] The incidence in the developing world is on the riseattributable to increased life expectancy from communicable disease control, excess tobacco and alcohol consumption (risk factors for head and neck cancers) and HIV. [1] Treatment outcomes for patients treated in developing world versus developed world countries are quite different. Farmer et al. [20] found an association between cancer fatality rates and national income -the cancer case fatality rate in low-income countries is 75%, as opposed to 45% in high-income countries.
HNSCC is also the third most common head and neck malignancy for patients with HIV (after Kaposi's sarcoma and non-Hodgkin's lymphoma). [21] Although not an AIDS-defining illness, HNSCC is seen in excess among HIV-infected individuals, and is sometimes referred to an 'opportunistic' cancer. Patients with a suspicious persistent head and neck lesion should always be referred for further investigation.
In addition, there is growing evidence that confirms the causative relationship between oncogenic human papillomavirus (HPV) and oropharyngeal squamous carcinoma in the general population. The prevalence of HPV in oropharyngeal cancer, especially tonsillar cancer, is as high as 90%. HPV type 16 is most commonly involved. An unexpected and positive finding in the literature is HPV-positive HNSCC being associated with high-stage tumours, but actually having better survival. [21] There are many challenges that face ENT specialists -as clinicians who value contribution to individual patients, and in the broader field of population health. Issues highlighted in this editorial help give insight into the current ENT perspective, notwithstanding other important topics that have not been addressed.
The SA Society of Otorhinolaryngology, Head and Neck Surgery is well established and includes private and public specialists, as well as registrars in training. Also established is the National Registrar Society, a subsidiary body that is managed independently by elected registrars and includes a national database and interactive website. Both divisions are actively committed to maintaining a high standard of training.
